|
BOSTON, October 30, 2025 – The Institute for Clinical and Economic Review (ICER) today released a Final Evidence Report assessing the comparative clinical effectiveness and value of brensocatib (Brinsupri™, Insmed Incorporated) for the treatment of non-cystic fibrosis bronchiectasis (NCFB).
ICER’s report on this therapy was the subject of the September 2025 public meeting of the CTAF, one of ICER’s three independent evidence appraisal committees.
Downloads: Final Evidence Report | Report-at-a-Glance | Policy Recommendations
“Brensocatib provides a clear benefit to patients dealing with NCFB, who have waited a long time for a therapy targeted to their condition,” said ICER’s Chief Scientific Officer and Director of Health Technology Assessment Methods and Engagement Dan Ollendorf, PhD, MPH. “Yet there are significant uncertainties regarding the extent of brensocatib’s benefits, and its current price does not align with even the most optimistic take on those benefits. Manufacturers must responsibly price new therapies like brensocatib so that patients have fair access to those therapies and a sustainable health care system for everyone.”
ICER’s Public Meeting: Voting Results on Clinical Effectiveness and Benefits Beyond Health
ICER assessed, and the independent appraisal committee voted on the evidence for the net health benefit of brensocatib:
- The panelists unanimously (11-0) found that current evidence is adequate to demonstrate a net health benefit of brensocatib as an add-on therapy to usual care in comparison to usual care alone.
Panel members also weighed potential benefits and disadvantages beyond the direct health effects and weighed special ethical priorities. Voting highlighted the following as particularly important for payers and other policymakers to note:
- There is substantial unmet need despite currently available treatments.
ICER’s Public Meeting: Voting Results on Long-Term Value for Money
The FDA approved brensocatib for NCFB on August 12, 2025. The manufacturer announced a US list price of $88,000 annually.
After reviewing the clinical evidence and considering the treatments’ benefits beyond health noted above, the CTAF evaluated the long-term value of brensocatib at its current pricing:
- The panelists unanimously (11-0) found that at its current pricing, brensocatib as an add-on therapy to usual care represents “low” long-term value for money.
Key Policy Recommendations
ICER’s independent assessment of value informs the critical decisions that stakeholders across the US health system need to make around pricing and coverage. Following the voting session, a policy roundtable of experts — including clinical experts, patients and patient advocates, and representatives from US payers — convened to discuss the pricing implications and recommendations to ensure fair access. Key recommendations stemming from the roundtable discussion include:
- Manufacturers should set prices that will foster affordability and access for all patients by aligning prices with the patient-centered value of their treatments. At $88,000 per year, the launch price for brensocatib is substantially higher than a cost-effective price. There needs to be more attention to the deleterious effect of high prices on patient access.
- Payers should support reimbursement for daily home therapies for NCFB, which continue to be a critical component of NCFB care. Respiratory therapists and other professionals such as nurse case managers have important roles in helping patients conduct airway clearance and other supportive care consistently and effectively.
- Clinicians and clinical societies should create United States-focused treatment guidelines for patients with NCFB.
ICER’s detailed set of policy recommendations is available in the Final Evidence Report and in the standalone Policy Recommendations document.
| 
